- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- NATCO PHARMA - IPCA LABS
NATCO PHARMA vs IPCA LABS - Comparison Results
Current Valuations
| NATCO PHARMA | IPCA LABS | NATCO PHARMA/ IPCA LABS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 19.3 | 35.0 | 55.0% | View Chart |
| P/BV | x | 18.5 | 3.3 | 555.0% | View Chart |
| Dividend Yield | % | 0.6 | 0.2 | 401.2% |
Financials
 NATCO PHARMA  IPCA LABS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NATCO PHARMA Mar-14 |
IPCA LABS Mar-17 |
NATCO PHARMA/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 877 | 643 | 136.4% | |
| Low | Rs | 424 | 503 | 84.2% | |
| Sales per share (Unadj.) | Rs | 223.4 | 254.4 | 87.8% | |
| Earnings per share (Unadj.) | Rs | 31.1 | 16.1 | 193.3% | |
| Cash flow per share (Unadj.) | Rs | 40.3 | 29.8 | 135.3% | |
| Dividends per share (Unadj.) | Rs | 5.00 | 1.00 | 500.0% | |
| Dividend yield (eoy) | % | 0.8 | 0.2 | 440.5% | |
| Book value per share (Unadj.) | Rs | 219.5 | 194.6 | 112.8% | |
| Shares outstanding (eoy) | m | 33.07 | 126.20 | 26.2% | |
| Bonus/Rights/Conversions | PA | - | - | ||
| Price / Sales ratio | x | 2.9 | 2.3 | 129.2% | |
| Avg P/E ratio | x | 20.9 | 35.7 | 58.7% | |
| P/CF ratio (eoy) | x | 16.1 | 19.2 | 83.9% | |
| Price / Book Value ratio | x | 3.0 | 2.9 | 100.6% | |
| Dividend payout | % | 16.1 | 6.2 | 258.6% | |
| Avg Mkt Cap | Rs m | 21,504 | 72,300 | 29.7% | |
| No. of employees | `000 | NA | 13.3 | 0.0% | |
| Total wages/salary | Rs m | 1,128 | 6,960 | 16.2% | |
| Avg. sales/employee | Rs Th | NM | 2,413.5 | - | |
| Avg. wages/employee | Rs Th | NM | 523.2 | - | |
| Avg. net profit/employee | Rs Th | NM | 152.4 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 7,389 | 32,106 | 23.0% | |
| Other income | Rs m | 167 | 226 | 74.0% | |
| Total revenues | Rs m | 7,556 | 32,332 | 23.4% | |
| Gross profit | Rs m | 1,793 | 4,448 | 40.3% | |
| Depreciation | Rs m | 304 | 1,730 | 17.6% | |
| Interest | Rs m | 366 | 241 | 152.1% | |
| Profit before tax | Rs m | 1,290 | 2,703 | 47.7% | |
| Minority Interest | Rs m | 46 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 309 | 675 | 45.7% | |
| Profit after tax | Rs m | 1,027 | 2,028 | 50.7% | |
| Gross profit margin | % | 24.3 | 13.9 | 175.2% | |
| Effective tax rate | % | 23.9 | 25.0 | 95.8% | |
| Net profit margin | % | 13.9 | 6.3 | 220.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,681 | 17,340 | 21.2% | |
| Current liabilities | Rs m | 3,123 | 9,559 | 32.7% | |
| Net working cap to sales | % | 7.6 | 24.2 | 31.2% | |
| Current ratio | x | 1.2 | 1.8 | 65.0% | |
| Inventory Days | Days | 89 | 100 | 89.2% | |
| Debtors Days | Days | 59 | 57 | 103.2% | |
| Net fixed assets | Rs m | 7,685 | 20,779 | 37.0% | |
| Share capital | Rs m | 331 | 252 | 131.0% | |
| "Free" reserves | Rs m | 6,670 | 24,499 | 27.2% | |
| Net worth | Rs m | 7,259 | 24,553 | 29.6% | |
| Long term debt | Rs m | 955 | 3,517 | 27.1% | |
| Total assets | Rs m | 11,957 | 39,595 | 30.2% | |
| Interest coverage | x | 4.5 | 12.2 | 37.0% | |
| Debt to equity ratio | x | 0.1 | 0.1 | 91.8% | |
| Sales to assets ratio | x | 0.6 | 0.8 | 76.2% | |
| Return on assets | % | 11.7 | 5.7 | 203.4% | |
| Return on equity | % | 14.2 | 8.3 | 171.4% | |
| Return on capital | % | 20.7 | 10.5 | 197.6% | |
| Exports to sales | % | 39.4 | 48.6 | 80.9% | |
| Imports to sales | % | 5.7 | 14.2 | 40.0% | |
| Exports (fob) | Rs m | 2,908 | 15,617 | 18.6% | |
| Imports (cif) | Rs m | 421 | 4,571 | 9.2% | |
| Fx inflow | Rs m | 3,445 | 15,617 | 22.1% | |
| Fx outflow | Rs m | 703 | 5,828 | 12.1% | |
| Net fx | Rs m | 2,743 | 9,790 | 28.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,440 | 2,764 | 52.1% | |
| From Investments | Rs m | -1,089 | -1,432 | 76.1% | |
| From Financial Activity | Rs m | -353 | -1,591 | 22.2% | |
| Net Cashflow | Rs m | -1 | -259 | 0.6% | |
Share Holding
| Indian Promoters | % | 52.0 | 45.9 | 113.4% | |
| Foreign collaborators | % | 1.5 | 0.0 | - | |
| Indian inst/Mut Fund | % | 7.8 | 11.4 | 68.8% | |
| FIIs | % | 16.6 | 25.3 | 65.7% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 26.0 | 17.4 | 149.4% | |
| Shareholders | 25,395 | 36,892 | 68.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare NATCO PHARMA With: DIVIS LABORATORIES WOCKHARDT LTD. VENUS REMEDIES PLETHICO PHARMA GLENMARK PHARMA
Compare NATCO PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)
After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.
Related Views on News
IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%
May 30, 2018 | Updated on May 30, 2018For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%
May 25, 2018 | Updated on May 25, 2018For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)
Jun 13, 2018The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.
Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)
Jun 14, 2018After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.
GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)
Jun 13, 2018Though it will bring transparency in their pricing and that in itself will be a welcome move.
Should You Invest In Mirae Asset Healthcare Fund?(Outside View)
Jun 15, 2018Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.
This Behaviour is Injurious to Wealth Building(Sector Info)
Jun 13, 2018Blindly following the herd can be the biggest wealth destroyer.
More|
| |
NATCO PHARMA SHARE PRICE
Jun 25, 2018 03:35 PM
TRACK NATCO PHARMA
- Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NATCO PHARMA
NATCO PHARMA 8-QTR ANALYSIS
COMPARE NATCO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.